GlassScriptPhysician profile
Abigail Chua
NPI 1821381385
$79,761.62
in general payments reported to CMS, 2019-2025
9 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $27K · 2021: $831 · 2023: $1,332 · 2024: $175 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $2,725 · Food and Beverage: $813 · Travel and Lodging: $54.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,062.50 |
| Consulting Fee | $2,725.00 |
| Food and Beverage | $813.35 |
| Travel and Lodging | $54.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23,866.22 | 2019-2021 | |
| Lilly USA, LLC | $21,453.01 | 2019-2020 | |
| Abbvie INC. | $18,978.79 | 2023-2025 | Qulipta, Ubrelvy |
| Allergan, INC. | $13,759.38 | 2019-2020 | |
| Pfizer INC. | $1,525.00 | 2025 | |
| Impel Pharmaceuticals INC. | $131.66 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $19.91 | 2025 | Symbravo |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2019 | |
| Bausch Health US, LLC | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.